Bradycardia News and Research

RSS

Bradycardia, ("heart slowness"), as applied to adult medicine, is defined as a resting heart rate of under 60 beats per minute, though it is seldom symptomatic until the rate drops below 50 beat/min.

China with the world: COVID-19 experts dialogues - the 4th talk transcript

Q (Prof. Singer): What do you think about the comorbidities and the age of the patients in the treatment of COVID-19? Is the mortality higher in elderly patients as it is reported from recent papers?

From Mindray 15 Apr 2020

Patients with anorexia nervosa face similar health complications as their counterparts with low BMI

Adolescents and young adults with anorexia nervosa whose weight is in the healthy, overweight or obese ranges face similar cardiovascular and other health complications as their counterparts with low body mass index (BMI), according to a new study led by researchers at UCSF.

6 Nov 2019

Complications after cardiac device implantation vary widely among hospitals

The chances of patients experiencing complications after having a cardiac device implanted vary according to where they have the procedure.

30 Jul 2019

Anti-arrhythmic agents linked to increased risk of falls

Anti-arrhythmic drugs, particularly those used to treat atrial fibrillation, could increase the risk of fall-related injuries, a new study found.

29 Jul 2019

Invasive surgeries could be avoided with new pacemakers powered by heartbeats

Researchers have developed a small, flexible, elastic skeleton bound to two piezoelectric composites, which uses the electrical activity of the heart for power.

22 Feb 2019

Newly developed gene therapy helps decelerate aging process

Aging is a leading risk factor for a number of debilitating conditions, including heart disease, cancer and Alzheimer's disease, to name a few. This makes the need for anti-aging therapies all the more urgent. Now, Salk Institute researchers have developed a new gene therapy to help decelerate the aging process.

20 Feb 2019

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

Takeda announces positive Phase 3 ALTA-1L data in first-line therapy for advanced ALK+ NSCLC

Takeda Pharmaceutical Company Limited today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients.

22 Oct 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

Brigatinib drug may offer first-line treatment option for ALK-positive NSCLC

Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.

26 Sep 2018

CHMP adopts positive opinion of Takeda’s ALUNBRIG for treatment of ALK+ non-small cell lung cancer

Takeda Pharmaceutical Company Limited today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion, recommending the full approval of ALUNBRIG® as a monotherapy for the treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer previously treated with crizotinib.

24 Sep 2018

Researchers raise serious concerns about the accuracy of two baby monitors

Researchers who tested two commercially available baby monitors are raising serious concerns about the accuracy of these products, which are marketed to parents, but are not regulated by the U.S. Food & Drug Administration.

21 Aug 2018

Aggressive lowering of blood pressure reduces MCI risk, study shows

Significant reductions in the risk of mild cognitive impairment (MCI), and the combination of MCI and dementia, have been shown for the first time through aggressive lowering of systolic blood pressure in new research results from the federally-funded SPRINT MIND Study reported at the Alzheimer's Association International Conference 2018 in Chicago.

25 Jul 2018

FDA approves new treatment to mitigate opioid withdrawal symptoms in adults

The U.S. Food and Drug Administration today approved Lucemyra (lofexidine hydrochloride) for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults.

17 May 2018

New leadless pacemakers carry reduced risks of complications and are less invasive

Loyola Medicine is now offering select heart patients leadless pacemakers that are less invasive and cause fewer complications than standard pacemakers.

9 Apr 2018

ACADIA Pharmaceuticals announces results from Phase II study of antipsychotic in Alzheimer's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system (CNS) disorders, today announced the presentation of data from the Phase II -019 Study of pimavanserin in Alzheimer's disease psychosis at the 10th Clinical Trials on Alzheimer's Disease meeting in Boston.

3 Nov 2017

World’s smallest pacemaker for cardiology patients now offered at Medical City Dallas

Medical City Dallas is now offering the world’s smallest pacemaker for cardiology patients. The Micra pacemaker is a new type of heart device that provides patients with the most advanced pacing technology at one-tenth the size of a traditional pacemaker.

6 Oct 2017

U.S. FDA approves updated labeling for pan-genotypic single tablet regimen for HCV/HIV co-infected patients

Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration has approved updated labeling for Epclusa (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV.

1 Aug 2017

Pacemakers and other cardiac devices reveal time, cause of death in some forensic cases

Pacemakers and other cardiac devices can help solve forensic cases, according to a study presented today at EHRA EUROPACE - CARDIOSTIM 2017. Devices revealed the time and cause of death in some cases where autopsy failed to do so.

20 Jun 2017

Takeda announces accelerated approval from FDA for new lung cancer treatment

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that ALUNBRIG (brigatinib) has received Accelerated Approval from the U.S. Food and Drug Administration for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

28 Apr 2017